Form 4: Lumos Pharma Chief Scientific Officer Exercises and Disposes of Stock Options in Merger
Merger Related Filing
Lumos Pharma's Chief Scientific Officer, John C. McKew, exercised and disposed of various stock options and common stock holdings as part of a merger agreement with DPV Parent, Inc.
Summary
- John C. McKew, Chief Scientific Officer of Lumos Pharma, engaged in multiple transactions involving stock options and common stock on December 12, 2024.
- These transactions included the exercise of stock options at various prices, ranging from $2.45 to $17.35, and the subsequent disposal of these shares.
- The disposal of shares and options was part of a merger agreement with DPV Parent, Inc., where shares were exchanged for $4.25 in cash per share plus one contingent value right (CVR).
- Restricted stock units (RSUs) were also cancelled and received the cash amount plus one CVR per RSU.
- In-the-money options were cancelled and received cash equal to the difference between the cash amount and the exercise price, plus one CVR per share.
- Out-of-money options were cancelled without any cash payment or CVRs.
Sentiment
Score: 7
Explanation: The document is a factual disclosure of transactions related to a merger, which is a neutral event. The sentiment is slightly positive as the merger is likely a positive outcome for shareholders.
Future Outlook
The document primarily details past transactions related to the merger and does not provide forward-looking statements.
Industry Context
This filing is a standard disclosure related to a merger, reflecting the typical process of stock and option handling during such transactions.
Comparison to Industry Standards
- The handling of stock options and RSUs in this merger is consistent with standard practices in corporate acquisitions.
- The exchange of shares for cash and contingent value rights is a common approach in mergers, particularly in the biotech and pharmaceutical sectors.
- The cancellation of out-of-money options without compensation is also a standard procedure in such transactions.
Stakeholder Impact
- Shareholders received $4.25 per share in cash plus one contingent value right.
- Employees holding stock options and RSUs were impacted by the merger agreement, receiving cash and CVRs for in-the-money options and RSUs.
Key Dates
| Date | Description |
|---|---|
| 2024-10-22 | Date of the Merger Agreement between Lumos Pharma, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC. |
| 2024-12-12 | Date of stock option exercises and disposals by John C. McKew. |
| 2024-12-13 | Date of filing of the document. |
| 2026-07-11 | Expiration date of one of the stock options. |
| 2028-01-18 | Expiration date of one of the stock options. |
| 2028-08-29 | Expiration date of one of the stock options. |
| 2030-03-31 | Expiration date of one of the stock options. |
| 2031-01-31 | Expiration date of one of the stock options. |
| 2032-01-31 | Expiration date of one of the stock options. |
| 2034-03-31 | Expiration date of one of the stock options. |
Keywords
Lumos Pharma, stock options, merger, DPV Parent, contingent value right, John C. McKew, Chief Scientific Officer, stock disposal, cash payment, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.